Susquehanna initiates coverage on SciClone Pharmaceuticals (Nasdaq: SCLN) with a Neutral.

Susquehanna analyst says, "Our rating is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE